These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1540 related articles for article (PubMed ID: 28233802)

  • 1. Targeting neoantigens to augment antitumour immunity.
    Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
    Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Neoantigens for Personalised Immunotherapy.
    Pritchard AL
    BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor neoantigens: building a framework for personalized cancer immunotherapy.
    Gubin MM; Artyomov MN; Mardis ER; Schreiber RD
    J Clin Invest; 2015 Sep; 125(9):3413-21. PubMed ID: 26258412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy targeting neoantigens.
    Lu YC; Robbins PF
    Semin Immunol; 2016 Feb; 28(1):22-7. PubMed ID: 26653770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
    Sun Z; Chen F; Meng F; Wei J; Liu B
    Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
    Ward JP; Gubin MM; Schreiber RD
    Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New emerging targets in cancer immunotherapy: the role of neoantigens.
    De Mattos-Arruda L; Blanco-Heredia J; Aguilar-Gurrieri C; Carrillo J; Blanco J
    ESMO Open; 2020 Apr; 4(Suppl 3):e000684. PubMed ID: 32269031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing neoantigens for personalized cancer immunotherapy.
    Capietto AH; Jhunjhunwala S; Delamarre L
    Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Neoantigens.
    Schumacher TN; Scheper W; Kvistborg P
    Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
    Bethune MT; Joglekar AV
    Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment.
    van Belzen IAEM; Kesmir C
    Immunogenetics; 2019 Feb; 71(2):71-86. PubMed ID: 30232514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of neoantigens in response to immune checkpoint blockade.
    Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
    Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of tumour peptide vaccines: From universalization to personalization.
    Ma M; Liu J; Jin S; Wang L
    Scand J Immunol; 2020 Jun; 91(6):e12875. PubMed ID: 32090366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Links between genetics and immunology: mutations and antigens.
    Ayyoub M
    Bull Acad Natl Med; 2016 Jan; 200(1):67-79. PubMed ID: 29889414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.